Price movement over the last 24 hours
Aspen Aerogels Inc vs Humana Inc — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while Humana Inc trades at $398 (market cap $47.09B). The key difference: Humana Inc is far larger — about 110.1× Aspen Aerogels Inc's market cap, and Humana Inc pays a 0.9% dividend while Aspen Aerogels Inc pays none. Which is the better fit depends on your goals.
| ASPN | HUM | |
|---|---|---|
Market Cap | $427.65M | $47.09B |
Sector | Technology | Health |
52-Week High | $8.82 | $409.42 |
52-Week Low | $2.57 | $163.67 |
Enterprise Value | $382.60M | $56.13B |
Dividend Yield | — | 0.9% |
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
Humana (HUM) trades at $392.22, down 1.39% on the day, with technical indicators showing a bullish trend despite near-term overbought signals. The company reported revenue growth to $129.66 billion in 2025 but faces margin compression, with net income margin declining to 0.82%. Recent news highlights strategic shifts, including the $900 million divestiture of its Gentiva stake and expansion of Medicaid contracts, while legal investigations into fiduciary duties and healthcare cost disclosures present headwinds.
The stock's outlook is mixed: bullish technicals and revenue growth contrast with margin pressures and legal risks. Analysts are cautious, with a consensus price target of $327.07 below the current price, suggesting limited upside. Investment opportunities lie in Humana's strategic focus on profitability and CenterWell growth, but risks include regulatory scrutiny and execution challenges in a competitive healthcare landscape.
Trailing returns across standard periods
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →